04:15 AM EDT, 08/11/2025 (MT Newswires) -- Novartis ( NVS ) said Monday that two phase III trials assessing ianalumab in adults with active Sjogren's disease met the primary endpoint of showing "statistically significant" improvements in disease activity.

Ianalumab was "well tolerated" and showed a "favorable" safety profile in Sjogren's disease, a chronic and disabling autoimmune disease, the company said.

Novartis ( NVS ) intends to present the data at an upcoming medical meeting and submit ianalumab to health authorities globally.

The company's shares were up 1.6% in recent premarket activity.